{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:04:32Z","timestamp":1789049072262,"version":"build-2803163510"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ctrv.2024.102801","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T17:45:47Z","timestamp":1721238347000},"page":"102801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Targeting HIF-2\u03b1 and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma"],"prefix":"10.1016","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-7418","authenticated-orcid":false,"given":"Patricia","family":"Rioja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rey-Cardenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"De Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctrv.2024.102801_b0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102801_b0010","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s00345-018-2447-8","article-title":"WHO\/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies","volume":"36","author":"Warren","year":"2018","journal-title":"World J Urol [Internet]"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102801_b0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semcancer.2012.06.001","article-title":"The VHL\/HIF axis in clear cell renal carcinoma","volume":"23","author":"Shen","year":"2013","journal-title":"Semin Cancer Biol [Internet]"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102801_b0020","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nrc2502","article-title":"The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer","volume":"8","author":"Kaelin","year":"2008","journal-title":"Nat Rev Cancer [Internet]"},{"key":"10.1016\/j.ctrv.2024.102801_b0025","first-page":"195","article-title":"Targeting Hypoxia-Inducible Factor-1 (HIF-1) in Cancer: Emerging Therapeutic Strategies and Pathway Regulation","volume":"17","author":"Wong","year":"2024","journal-title":"Pharm [Internet]"},{"issue":"22","key":"10.1016\/j.ctrv.2024.102801_b0030","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-22-1054","article-title":"FDA Approval Summary: Belzutifan for von Hippel-Lindau disease associated tumors","volume":"28","author":"Fallah","year":"2022","journal-title":"Clin Cancer Res [Internet]."},{"key":"10.1016\/j.ctrv.2024.102801_b0035","unstructured":"FDA approves belzutifan for advanced renal cell carcinoma | FDA [Internet]. [cited 2024 Mar 17]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-belzutifan-advanced-renal-cell-carcinoma."},{"issue":"22","key":"10.1016\/j.ctrv.2024.102801_b0040","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med [Internet]"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2024.102801_b0045","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1200\/JCO.2022.40.16_suppl.4509","article-title":"Phase 1 LITESPARK-001 (MK-6482-001) study of belzutifan in advanced solid tumors: Update of the clear cell renal cell carcinoma (ccRCC) cohort with more than 3 years of total follow-up","volume":"40","author":"Jonasch","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9374","key":"10.1016\/j.ctrv.2024.102801_b0050","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","article-title":"von Hippel-Lindau disease","volume":"361","author":"Lonser","year":"2003","journal-title":"Lancet (London, England) [Internet]"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102801_b0055","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ng.2699","article-title":"Integrated molecular analysis of clear-cell renal cell carcinoma","volume":"45","author":"Sato","year":"2013","journal-title":"Nat Genet [Internet]"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102801_b0060","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/modpathol.2017.72","article-title":"Renal cell tumors with clear cell histology and intact VHL and chromosome 3p: A histological review of tumors from the Cancer Genome Atlas database","volume":"30","author":"Favazza","year":"2017","journal-title":"Mod Pathol"},{"issue":"36","key":"10.1016\/j.ctrv.2024.102801_b0065","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1200\/JCO.2018.79.2549","article-title":"Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma","volume":"36","author":"Hsieh","year":"2018","journal-title":"J Clin Oncol [Internet]"},{"issue":"36","key":"10.1016\/j.ctrv.2024.102801_b0070","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1200\/JCO.2018.79.2531","article-title":"Non-Clear cell renal cell carcinomas: from shadow to light","volume":"36","author":"Albiges","year":"2018","journal-title":"J Clin Oncol [Internet]"},{"key":"10.1016\/j.ctrv.2024.102801_b0075","doi-asserted-by":"crossref","unstructured":"WM L, PT S, CJ R, CJ C, SS F, C D, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med [Internet]. 2016 Jan 14;374(2):135\u201345. https:\/\/pubmed.ncbi.nlm.nih.gov\/26536169\/ [cited 2024 Mar 17].","DOI":"10.1056\/NEJMoa1505917"},{"issue":"6733","key":"10.1016\/j.ctrv.2024.102801_b0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature [Internet]"},{"key":"10.1016\/j.ctrv.2024.102801_b0085","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev.cellbio.15.1.551","article-title":"Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1","volume":"15","author":"Semenza","year":"1999","journal-title":"Annu Rev Cell Dev Biol [Internet]"},{"issue":"24","key":"10.1016\/j.ctrv.2024.102801_b0090","doi-asserted-by":"crossref","first-page":"9361","DOI":"10.1128\/MCB.23.24.9361-9374.2003","article-title":"Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation","volume":"23","author":"Hu","year":"2003","journal-title":"Mol Cell Biol [Internet]"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102801_b0095","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0092-8674(01)00507-4","article-title":"C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation","volume":"107","author":"Epstein","year":"2001","journal-title":"Cell [Internet]"},{"issue":"5516","key":"10.1016\/j.ctrv.2024.102801_b0100","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science [Internet]"},{"issue":"16","key":"10.1016\/j.ctrv.2024.102801_b0105","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1007\/s00018-007-7082-2","article-title":"The role of hypoxia-inducible factors in cancer","volume":"64","author":"Maynard","year":"2007","journal-title":"Cell Mol Life Sci [Internet]"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102801_b0110","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.4161\/cbt.7.10.6583","article-title":"Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis","volume":"7","author":"Chun","year":"2008","journal-title":"Cancer Biol Ther [Internet]."},{"issue":"5","key":"10.1016\/j.ctrv.2024.102801_b0115","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(02)00071-5","article-title":"HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron","volume":"1","author":"Mandriota","year":"2002","journal-title":"Cancer Cell [Internet]"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102801_b0120","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","article-title":"The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma","volume":"23","author":"Ricketts","year":"2018","journal-title":"Cell Rep [Internet]"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102801_b0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/KCA-170008","article-title":"Molecular Classification of Renal Cell Carcinoma and Its Implication in Future Clinical Practice","volume":"1","author":"Casuscelli","year":"2017","journal-title":"Kidney Cancer [Internet]."},{"issue":"7","key":"10.1016\/j.ctrv.2024.102801_b0130","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41588-021-00887-y","article-title":"The HIF complex recruits the histone methyltransferase SET1B to activate specific hypoxia-inducible genes","volume":"53","author":"Ortmann","year":"2021","journal-title":"Nat Genet [Internet]"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102801_b0135","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","article-title":"Targeting the HIF2-VEGF axis in renal cell carcinoma","volume":"26","author":"Choueiri","year":"2020","journal-title":"Nat Med [Internet]"},{"issue":"18","key":"10.1016\/j.ctrv.2024.102801_b0140","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1128\/MCB.00090-16","article-title":"The Zinc Finger of Prolyl Hydroxylase Domain Protein 2 Is Essential for Efficient Hydroxylation of Hypoxia-Inducible Factor \u03b1","volume":"36","author":"Arsenault","year":"2016","journal-title":"Mol Cell Biol [Internet]"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102801_b0145","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/j.1582-4934.2011.01484.x","article-title":"Hypoxia-inducible factor 1-mediated human GATA1 induction promotes erythroid differentiation under hypoxic conditions","volume":"16","author":"Zhang","year":"2012","journal-title":"J Cell Mol Med [Internet]"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102801_b0150","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.3324\/haematol.2018.192518","article-title":"Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts","volume":"103","author":"Valent","year":"2018","journal-title":"Haematologica [Internet]"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102801_b0155","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0092-8674(93)90414-L","article-title":"JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin","volume":"74","author":"Witthuhn","year":"1993","journal-title":"Cell [Internet]"},{"issue":"9 Suppl. 5(S5)","key":"10.1016\/j.ctrv.2024.102801_b0160","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1634\/theoncologist.9-90005-18","article-title":"The erythropoietin receptor and its expression in tumor cells and other tissues","volume":"1","author":"Farrell","year":"2004","journal-title":"Oncologist [Internet]"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102801_b0165","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1523-1755.2000.00211.x","article-title":"Erythropoietin stimulates proliferation of human renal carcinoma cells","volume":"58","author":"Westenfelder","year":"2000","journal-title":"Kidney Int [Internet]"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102801_b0170","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/bjc.2012.42","article-title":"Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer","volume":"106","author":"Aapro","year":"2012","journal-title":"Br J Cancer [Internet]"},{"issue":"Nov","key":"10.1016\/j.ctrv.2024.102801_b0175","article-title":"Erythropoietin and cancer: the unintended consequences of anemia correction","volume":"5","author":"Debeljak","year":"2014","journal-title":"Front Immunol [Internet]"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102801_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10409238.2013.838205","article-title":"Transcriptional regulation by hypoxia inducible factors","volume":"49","author":"Dengler","year":"2014","journal-title":"Crit Rev Biochem Mol Biol [Internet]"},{"issue":"35","key":"10.1016\/j.ctrv.2024.102801_b0185","doi-asserted-by":"crossref","first-page":"25703","DOI":"10.1074\/jbc.M602329200","article-title":"Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development","volume":"281","author":"Yoon","year":"2006","journal-title":"J Biol Chem [Internet]"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102801_b0190","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1073\/pnas.0608382104","article-title":"Acute postnatal ablation of Hif-2alpha results in anemia","volume":"104","author":"Gruber","year":"2007","journal-title":"Proc Natl Acad Sci U S A [Internet]"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102801_b0195","article-title":"Systems biology of oxygen homeostasis","volume":"9","author":"Samanta","year":"2017","journal-title":"Wiley Interdiscip Rev Syst Biol Med [Internet]"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102801_b0200","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1172\/JCI38499","article-title":"HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice","volume":"119","author":"Mastrogiannaki","year":"2009","journal-title":"J Clin Invest [Internet]"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102801_b0205","first-page":"1","article-title":"A biomathematical model of human erythropoiesis and iron metabolism","volume":"10","author":"Schirm","year":"2020","journal-title":"Sci Rep [Internet]"},{"key":"10.1016\/j.ctrv.2024.102801_b0210","doi-asserted-by":"crossref","unstructured":"Camaschella C. Iron-Deficiency Anemia. Longo DL, editor. [Internet]. 2015 May 7;372(19):1832\u201343. https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmra1401038 [cited 2023 Dec 18].","DOI":"10.1056\/NEJMra1401038"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102801_b0215","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000216844","article-title":"Expression of erythropoietin and its receptor in human renal cell carcinoma","volume":"30","author":"Papworth","year":"2009","journal-title":"Tumour Biol [Internet]"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102801_b0220","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2169\/internalmedicine.38.991","article-title":"Gene expression of erythropoietin in renal cell carcinoma","volume":"38","author":"Noguchi","year":"1999","journal-title":"Intern Med [Internet]"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102801_b0225","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3233\/KCA-170013","article-title":"Tissue expression of erythropoietin predicts survival rates in clear cell renal cell carcinoma","volume":"1","author":"Ferreira","year":"2017","journal-title":"Kidney cancer (Clifton Va) [Internet]"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102801_b0230","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1002\/ijc.22961","article-title":"Erythropoietin gene expression in renal carcinoma is considerably more frequent than paraneoplastic polycythemia","volume":"121","author":"Wiesener","year":"2007","journal-title":"Int J cancer [Internet]"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102801_b0235","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.V75.3.577.577","article-title":"Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia","volume":"75","author":"Da Silva","year":"1990","journal-title":"Blood [Internet]"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102801_b0240","first-page":"1","article-title":"Functional significance of erythropoietin in renal cell carcinoma","volume":"13","author":"Morais","year":"2013","journal-title":"BMC Cancer [Internet]"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102801_b0245","doi-asserted-by":"crossref","first-page":"340.e9","DOI":"10.1016\/j.urolonc.2015.01.010","article-title":"Decreased PBRM1 expression predicts unfavorable prognosis in patients with clear cell renal cell carcinoma","volume":"33","author":"Nam","year":"2015","journal-title":"Urol Oncol [Internet]"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102801_b0250","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm301847z","article-title":"Development of inhibitors of the PAS-B domain of the HIF-2\u03b1 transcription factor","volume":"56","author":"Rogers","year":"2013","journal-title":"J Med Chem [Internet]"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102801_b0255","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/emboj\/18.7.1905","article-title":"Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP\/p300","volume":"18","author":"Ema","year":"1999","journal-title":"EMBO J"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102801_b0260","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2\u03b1 Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J Clin Oncol [Internet]"},{"key":"#cr-split#-10.1016\/j.ctrv.2024.102801_b0265.1","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nberger T, Fandrey J, Prost-Fingerle K. Ways into Understanding HIF Inhibition. Cancers (Basel) [Internet]. 2021 Jan 1","DOI":"10.3390\/cancers13010159"},{"key":"#cr-split#-10.1016\/j.ctrv.2024.102801_b0265.2","unstructured":"13(1): 1-16. https:\/\/pubmed.ncbi.nlm.nih.gov\/33466454\/ [cited 2024 Mar 17]."},{"issue":"2","key":"10.1016\/j.ctrv.2024.102801_b0270","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1073\/pnas.0808092106","article-title":"Artificial ligand binding within the HIF2alpha PAS-B domain of the HIF2 transcription factor","volume":"106","author":"Scheuermann","year":"2009","journal-title":"Proc Natl Acad Sci U S A [Internet]"},{"issue":"18","key":"10.1016\/j.ctrv.2024.102801_b0275","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1158\/0008-5472.CAN-16-0473","article-title":"A Small-Molecule Antagonist of HIF2\u03b1 Is Efficacious in Preclinical Models of Renal Cell Carcinoma","volume":"76","author":"Wallace","year":"2016","journal-title":"Cancer Res [Internet]"},{"issue":"7627","key":"10.1016\/j.ctrv.2024.102801_b0280","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature19795","article-title":"On-target efficacy of a HIF-2\u03b1 antagonist in preclinical kidney cancer models","volume":"539","author":"Cho","year":"2016","journal-title":"Nature [Internet]"},{"key":"10.1016\/j.ctrv.2024.102801_b0285","first-page":"196","article-title":"Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort","volume":"2024","author":"Jonasch","year":"2024","journal-title":"Eur J Cancer [Internet]"},{"key":"10.1016\/j.ctrv.2024.102801_b0290","doi-asserted-by":"crossref","unstructured":"Jonasch E, Iliopoulos O, Rathmell WK, Narayan V, Maughan BL, Oudard S, et al. LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2\u03b1 inhibitor (HIF-2\u03b1), for von Hippel-Lindau (VHL) disease: Update with more than two years of follow-up data. 2022 Jun 2;40(16_suppl):4546\u20134546. https:\/\/doi.org\/101200\/JCO20224016_suppl4546.","DOI":"10.1200\/JCO.2022.40.16_suppl.4546"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102801_b0295","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3233\/KCA-230024","article-title":"Belzutifan versus Everolimus in Advanced Kidney Cancer: A Commentary on LITESPARK-005 Trial from ESMO 2023","volume":"8","author":"Gulati","year":"2024","journal-title":"Kidney Cancer (Clifton, Va) [Internet]"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102801_b0300","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S1470-2045(23)00097-9","article-title":"Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol [Internet]"},{"key":"10.1016\/j.ctrv.2024.102801_b0305","doi-asserted-by":"crossref","unstructured":"Choueiri TK, Bauer T, Merchan JR, McDermott DF, Figlin R, Arrowsmith E, et al. LBA87 Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC). Ann Oncol [Internet]. 2023 Oct 1;34:S1328\u20139. http:\/\/www.annalsofoncology.org\/article\/S0923753423042333\/fulltext [cited 2024 Jul 2].","DOI":"10.1016\/j.annonc.2023.10.089"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102801_b0310","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2217\/fon-2022-0802","article-title":"LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1\/PD-L1 therapy","volume":"19","author":"Motzer","year":"2023","journal-title":"Future Oncol [Internet]"},{"key":"10.1016\/j.ctrv.2024.102801_b0315","doi-asserted-by":"crossref","first-page":"S1011","DOI":"10.1016\/j.annonc.2023.09.1111","article-title":"1881O Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study","volume":"34","author":"Agarwal","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102801_b0325","unstructured":"fda, cder. HIGHLIGHTS OF PRESCRIBING INFORMATION. [cited 2023 Nov 28]; Available from: www.fda.gov\/medwatch."},{"issue":"29","key":"10.1016\/j.ctrv.2024.102801_b0330","doi-asserted-by":"crossref","first-page":"iv96","DOI":"10.1093\/annonc\/mdx758","article-title":"Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines","volume":"1","author":"Aapro","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T20:00:44Z","timestamp":1723665644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224001294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":66,"alternative-id":["S0305737224001294"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102801","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting HIF-2\u03b1 and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102801","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102801"}}